Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium potentiates the activity of antithrombin III, thereby inactivating thrombin and factor Xa, leading to inhibition of coagulation.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Intravenous: Initial bolus of 80 units/kg, then continuous infusion at 18 units/kg/h. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
The terminal elimination half-life of heparin is dose-dependent: approximately 30 minutes (low dose, e.g., 25 U/kg), 60 minutes (medium dose, 100 U/kg), and 150 minutes (high dose, 400 U/kg). Half-life increases with dose due to saturation of clearance mechanisms.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Heparin is cleared primarily via the reticuloendothelial system and liver, with minimal renal excretion. Unchanged heparin is not significantly excreted in urine. Biliary/fecal elimination is negligible.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant